Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition
Lo, Yungtai , Lester, Susan C. , Lanjewar, Sonali, Laurini, Javier A., Patel, Ami , Bhattarai, Ava, Ustun, Berrin , Harmon, Bryan, Kleer, Celina G. , Ross, Dara S. , Amin, Ali , Wang, Yihong , Bradley, Robert, Turashvili, Gulisa , Zeng, Jennifer , Baum, Jordan , Hakima, Laleh , Harigopal, Malini, Shin, Sandra J. , Abbott, Sara, Jaffer, Shabnam , Badve, Sunil Shankar, Khoury, Thaer , D’Alfonso, Timothy M. , Collins, Victoria , Towne, William S. , Gan, Yujun, Flieder, Andrea, Aldrees, Rana, Ngo, Marie-Hélène , Edema, Ukuemi, Sapna, Fnu , Schnitt, Stuart J. , Fineberg, Susan , Komforti, Miglena, Wang, Yihong , Turashvili, Gulisa , Ellis, Ian O. , Singh, Kamaljeet , Komforti, Miglena K. , Badve, Sunil , Ginter, Paula S. , Nassar, Aziza , Şahin, Ayşegül A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 20, 2024 | Volume: 148 | Issue: 10 | Pages: 1119-1125

10.5858/arpa.2023-0163-oa | PMID 38244086 Get It

Context.— The Nottingham Grading System (NGS) developed by Elston and Ellis is used to grade invasive breast cancer (IBC). Glandular (acinar)/tubule formation is a component of NGS. Objective.— To investigate the ability of pathologists to identify individual structures that should be classified as glandular (acinar)/tubule formation. Design.— A total of 58 hematoxylin-eosin photographic images of IBC with 1 structure circled were classified as tubules (41 cases) or nontubules (17 cases) by Professor Ellis. Images were sent as a PowerPoint (Microsoft) file to breast pathologists, who were provided with the World Health Organization definition of a tubule and asked to determine if a circled structure represented a tubule. Results.— Among 35 pathologists, the κ statistic for assessing agreement in evaluating the 58 images was 0.324 (95% CI, 0.314–0.335). The median concordance rate between a participating pathologist and Professor Ellis was 94.1% for evaluating 17 nontubule cases and 53.7% for 41 tubule cases. A total of 41% of the tubule cases were classified correctly by less than 50% of pathologists. Structures classified as tubules by Professor Ellis but often not recognized as tubules by pathologists included glands with complex architecture, mucinous carcinoma, and the “inverted tubule” pattern of micropapillary carcinoma. A total of 80% of participants reported that they did not have clarity on what represented a tubule. Conclusions.— We identified structures that should be included as tubules but that were not readily identified by pathologists. Greater concordance for identification of tubules might be obtained by providing more detailed images and descriptions of the types of structures included as tubules.
Does the number of social factors affect long-term patient-reported outcomes and satisfaction in those with cervical myelopathy? A QOD study
Park, Christine , Shaffrey, Christopher I. , Than, Khoi D. , Bisson, Erica F. , Sherrod, Brandon A. , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Chan, Andrew K. , Chou, Dean , Chaudhry, Nauman S. , Haid, Regis W., Mummaneni, Praveen V. , Michalopoulos, Giorgos D. , Bydon, Mohamad , Gottfried, Oren N., Michalopoulos, Georgios D, Michalopoulos, Giorgos , Park, Paul , Agarwal, Nitin

Mayo Clinic

Journal of Neurosurgery: Spine | January 20, 2024 | Volume: 40 | Issue: 4 | Pages: 428-438

10.3171/2023.11.spine23127 | PMID 38241683 Get It

OBJECTIVE It is not clear whether there is an additive effect of social factors in keeping patients with cervical spondylotic myelopathy (CSM) from achieving both a minimum clinically important difference (MCID) in outcomes and satisfaction after surgery. The aim of this study was to explore the effect of multiple social factors on postoperative outcomes and satisfaction. METHODS This was a multiinstitutional, retrospective study of the prospective Quality Outcomes Database (QOD) CSM cohort, which included patients aged 18 years or older who were diagnosed with primary CSM and underwent operative management. Social factors included race (White vs non-White), education (high school or below vs above), employment (employed vs not), and insurance (private vs nonprivate). Patients were considered to have improved from surgery if the following criteria were met: 1) they reported a score of 1 or 2 on the North American Spine Society index, and 2) they met the MCID in patient-reported outcomes (i.e., visual analog scale [VAS] neck and arm pain, Neck Disability Index [NDI], and EuroQol-5D [EQ-5D]). RESULTS Of the 1141 patients included in the study, 205 (18.0%) had 0, 347 (30.4%) had 1, 334 (29.3%) had 2, and 255 (22.3%) had 3 social factors. The 24-month follow-up rate was > 80% for all patient-reported outcomes. After adjusting for all relevant covariates (p < 0.02), patients with 1 or more social factors were less likely to improve from surgery in all measured outcomes including VAS neck pain (OR 0.90, 95% CI 0.83–0.99) and arm pain (OR 0.88, 95% CI 0.80–0.96); NDI (OR 0.90, 95% CI 0.83–0.98); and EQ-5D (OR 0.90, 95% CI 0.83–0.97) (all p < 0.05) compared to those without any social factors. Patients with 2 social factors (outcomes: neck pain OR 0.86, arm pain OR 0.81, NDI OR 0.84, EQ-5D OR 0.81; all p < 0.05) or 3 social factors (outcomes: neck pain OR 0.84, arm pain OR 0.84, NDI OR 0.84, EQ-5D OR 0.84; all p < 0.05) were more likely to fare worse in all outcomes compared to those with only 1 social factor. CONCLUSIONS Compared to those without any social factors, patients who had at least 1 social factor were less likely to achieve MCID and feel satisfied after surgery. The effect of social factors is additive in that patients with a higher number of factors are less likely to improve compared to those with only 1 social factor.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
Cynthia, X. , Sanati, Souzan , Leitch, A. Marilyn , Unzeitig, Gary, Fernández-Martínez, Aranzazu , Fan, Cheng , Gibbs, Richard A. , Dockter, Travis , Hahn, Olwen, Guenther, Joseph M., Caudle, Abigail S. , Crouch, Erika C., Tiersten, Amy , Mita, Monica , Razaq, Wajeeha, Rimawi, Mothaffar F. , Weiss, Anna , Perou, Charles M. , Carey, Lisa A. , Dockter, Travis J, Carey, Lisa A , Perou, Charles M , Rimawi, Mothaffar , Fernandez-Martinez, Aranzazu , Suman, Vera J. , Vij, Kiran R , Anurag, Meenakshi , Hoog, Jeremy , Watson, Mark A. , Hieken, Tina J. , Wang, Yang , Winer, Eric P. , Hunt, Kelly K. , Ellis, Matthew J. , Partridge, Ann H.

Mayo Clinic

JAMA Oncology | January 18, 2024 | Volume: 10 | Issue: 3 | Pages: 362

10.1001/jamaoncol.2023.6038 | PMID 38236590 Get It

Importance Adding fulvestrant to anastrozole (A+F) improved survival in postmenopausal women with advanced estrogen receptor (ER)–positive/ERBB2 (formerly HER2)–negative breast cancer. However, the combination has not been tested in early-stage disease. Objective To determine whether neoadjuvant fulvestrant or A+F increases the rate of pathologic complete response or ypT1-2N0/N1mic/Ki67 2.7% or less residual disease (referred to as endocrine-sensitive disease) over anastrozole alone. Design, Setting, and Participants A phase 3 randomized clinical trial assessing differences in clinical and correlative outcomes between each of the fulvestrant-containing arms and the anastrozole arm. Postmenopausal women with clinical stage II to III, ER-rich (Allred score 6-8 or &amp;gt;66%)/ERBB2-negative breast cancer were included. All analyses were based on data frozen on March 2, 2023. Interventions Patients received anastrozole, fulvestrant, or a combination for 6 months preoperatively. Tumor Ki67 was assessed at week 4 and optionally at week 12, and if greater than 10% at either time point, the patient switched to neoadjuvant chemotherapy or immediate surgery. Main Outcomes and Measures The primary outcome was the endocrine-sensitive disease rate (ESDR). A secondary outcome was the percentage change in Ki67 after 4 weeks of neoadjuvant endocrine therapy (NET) (week 4 Ki67 suppression). Results Between February 2014 and November 2018, 1362 female patients (mean [SD] age, 65.0 [8.2] years) were enrolled. Among the 1298 evaluable patients, ESDRs were 18.7% (95% CI, 15.1%-22.7%), 22.8% (95% CI, 18.9%-27.1%), and 20.5% (95% CI, 16.8%-24.6%) with anastrozole, fulvestrant, and A+F, respectively. Compared to anastrozole, neither fulvestrant-containing regimen significantly improved ESDR or week 4 Ki67 suppression. The rate of week 4 or week 12 Ki67 greater than 10% was 25.1%, 24.2%, and 15.7% with anastrozole, fulvestrant, and A+F, respectively. Pathologic complete response/residual cancer burden class I occurred in 8 of 167 patients and 17 of 167 patients, respectively (15.0%; 95% CI, 9.9%-21.3%), after switching to neoadjuvant chemotherapy due to week 4 or week 12 Ki67 greater than 10%. PAM50 subtyping derived from RNA sequencing of baseline biopsies available for 753 patients (58%) identified 394 luminal A, 304 luminal B, and 55 nonluminal tumors. A+F led to a greater week 4 Ki67 suppression than anastrozole alone in luminal B tumors (median [IQR], −90.4% [−95.2 to −81.9%] vs −76.7% [−89.0 to −55.6%]; P &amp;lt; .001), but not luminal A tumors. Thirty-six nonluminal tumors (65.5%) had a week 4 or week 12 Ki67 greater than 10%. Conclusions and Relevance In this randomized clinical trial, neither fulvestrant nor A+F significantly improved the 6-month ESDR over anastrozole in ER-rich/ERBB2-negative breast cancer. Aromatase inhibition remains the standard-of-care NET. Differential NET response by PAM50 subtype in exploratory analyses warrants further investigation. Trial Registration ClinicalTrials.gov Identifier: NCT01953588
2dGBH: Two-dimensional group Benjamini–Hochberg procedure for false discovery rate control in two-way multiple testing of genomic data
Yang, Lu , Chen, Jun , Chen, Jun , Wang, Pei

Mayo Clinic

Bioinformatics | January 17, 2024 | Volume: 40 | Issue: 2 | Pages: No page available

10.1093/bioinformatics/btae035 | PMID 38244568 Get It

Abstract Motivation Emerging omics technologies have introduced a two-way grouping structure in multiple testing, as seen in single-cell omics data, where the features can be grouped by either genes or cell types. Traditional multiple testing methods have limited ability to exploit such two-way grouping structure, leading to potential power loss. Results We propose a new 2D Group Benjamini–Hochberg (2dGBH) procedure to harness the two-way grouping structure in omics data, extending the traditional one-way adaptive GBH procedure. Using both simulated and real datasets, we show that 2dGBH effectively controls the false discovery rate across biologically relevant settings, and it is more powerful than the BH or q-value procedure and more robust than the one-way adaptive GBH procedure. Availability and implementation 2dGBH is available as an R package at: https://github.com/chloelulu/tdGBH. The analysis code and data are available at: https://github.com/chloelulu/tdGBH-paper.
Peptide-Guided Nanoparticle Drug Delivery for Cardiomyocytes
Taylor, Austin L., Shi, Haiwang , Zhou, Fang , Li, Pengsheng , Joshi, Jyotsna, Zhu, Wuqiang , Wang, Shu , Zhou, Fang , Zhu, Wuqiang , Wang, Shu , Li, Dong , Taylor, Austin

Mayo Clinic

Biology | January 16, 2024 | Volume: 13 | Issue: 1 | Pages: 47

10.3390/biology13010047 | PMID 38248477 Get It

Background: Nanoparticles (NPs) have been extensively utilized as a drug delivery system to control the release of therapeutic agents to treat cardiac injuries. However, despite the advantages of utilizing NP-based drug delivery for treating heart diseases, the current delivery system lacks specificity in targeting the cardiac tissue, thus limiting its application. Methods: We created three linear peptides, each consisting of 16–24 amino acids. These peptides were conjugated on the surface of NPs, resulting in the formation of cardiac targeting peptide (CTP)-NPs (designated as CTP-NP1, CTP-NP2, and CTP-NP3). To assess their effectiveness, we compared the binding efficiency of these three CTP-NPs to human and mouse cardiomyocytes. Additionally, we determined their distribution 24 h after injecting the CTP-NPs intravenously into adult C57BL/6J mice. Results: When compared to control NPs without CTP (Con-NPs), all three CTP-NPs exhibited significantly increased binding affinity to both human and mouse cardiomyocytes in vitro and enhanced retention in mouse hearts in vivo. A thorough assessment of the heart sections demonstrated that the binding specificity of CTP-NP3 to cardiomyocytes in vivo was significantly greater than that of Con-NPs. None of the three CTP-NPs were proven to cause cardiomyocyte apoptosis. Conclusions: Biocompatible and safe CTP-NP3 can target the heart via binding to cardiomyocytes. This approach of targeting specific molecules-coated NPs may help in delivering therapeutic compounds to cardiomyocytes for the treatment of heart diseases with high efficacy and low toxicity to other tissues.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Cerhan, James R. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Habermann, Thomas M. , Jaye, David L. , Burack, Richard , McDonnell, Timothy J. , Vega, Francisco , Chapman, Jennifer R. , Leonard, John P. , Bernal‐Mizrachi, Leon , Alderuccio, Juan Pablo , Riska, Shaun M., Gysbers, Brianna, Lunde, Julianne J. , Reicks, Tanner W., Ayers, Amy , O’Leary, Colin B. , Yost, Kathleen J. , Nowakowski, Grzegorz S. , Ruan, Jia , Koff, Jean L. , Thompson, Carrie A. , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Martin, Peter W., Flowers, Christopher R. , Burack, W Richard , Syrbu, Sergei , Vij, Kiran R , Bernal-Mizrachi, Leon , Witzig, T.E. , Weiner, George , Wang, Yucai , Alderuccio, Juan Pablo , Slager, Susan L , Liu, Hongfang , Chihara, Dai , Koff, Jean L , Casulo, Carla , Thompson, Carrie A , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Vega, Francisco , Link, Brian K , Habermann, Thomas , Jaye, David L , Syrbu, Sergei , Inghirami, Giorgio , Farooq, Umar , Witzig, Thomas E. , Weiner, George J. , Wang, Yucai , Slager, Susan L. , Larson, Melissa C. , Liu, Hongfang , Chihara, Dai , Casulo, Carla , Kahl, Brad S. , Nastoupil, Loretta J. , Martin, Peter

Mayo Clinic

American Journal of Hematology | January 13, 2024 | Volume: 99 | Issue: 3 | Pages: 408-421

10.1002/ajh.27202 | PMID 38217361 Get It

AbstractTo address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer
Stinchcombe, Thomas E. , Wang, Xiaofei , Damman, Bryce , Mentlick, Jennifer, Landreneau, Rodney J., Wigle, Dennis A. , Conti, Massimo , Ashrafi, Ahmad S., Liberman, Moïshe , Mitchell, John D. , Keenan, Robert J. , Wigle, Dennis, Jones, David R , Conti, Massimo , de Perrot, Marc , Mitchell, John D , Jones, David R. , BAUER, THOMAS L , Miller, Daniel , Altorki, Nasser Khaled , Damman, Bryce

Mayo Clinic

Journal of Clinical Oncology | January 12, 2024 | Volume: 42 | Issue: 10 | Pages: 1110-1113

10.1200/jco.23.01306 | PMID 38215351 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Patients with early-stage non–small-cell lung cancer (NSCLC) who undergo curative surgical resection are at risk for developing second primary lung cancer (SPLC). Cancer and Leukemia Group B 140503 (Alliance) was a multicenter, international, randomized, phase III trial in patients with stage T1aN0 NSCLC (using the TNM staging system seventh edition) and demonstrated the noninferiority for disease-free survival between sublobar resection (SLR) and lobar resection (LR). After surgery, patients underwent computed tomography surveillance as defined by the protocol. The determination of a SPLC was done by the treating physician and recorded in the study database. We performed an analysis of the rate of SPLC (per patient per year) and the 5-year cumulative incidence in the study population and within the SLR and LR arms. Median follow-up was 7 years. The rate per patient per year in the study population, in the SLR arm, and in the LR arm was 3.4% (95% CI, 2.9 to 4.1), 3.8% (95% CI, 2.9 to 4.9), and 3.1% (95% CI, 2.4 to 4.1), respectively. The estimated 5-year cumulative incidence of SPLC in the study population, SLR arm, and LR arm was 15.9% (95% CI, 12.9 to 18.9), 17.2% (95% CI, 12.7 to 21.5), and 14.7% (95% CI, 10.6 to 18.7), respectively.
Vacation Days Taken, Work During Vacation, and Burnout Among US Physicians
Sinsky, Christine A. , Trockel, Mickey , Carlasare, Lindsey E. , Shanafelt, Tait D. , Shanafelt, Tait D , Dyrbye, Liselotte N. , Wang, Hanhan , West, Colin P.

Mayo Clinic

JAMA Network Open | January 12, 2024 | Volume: 7 | Issue: 1 | Pages: e2351635

10.1001/jamanetworkopen.2023.51635 | PMID 38214928 Get It

ImportanceVacation has been shown to be an important restorative activity in the general population; less is known about physicians’ vacation behaviors and their association with burnout and professional fulfillment.ObjectiveTo examine the number of vacation days taken per year and the magnitude of physician work while on vacation and their association with physician burnout and professional fulfillment, by individual and organizational characteristics.Design, Setting, and ParticipantsThis cross-sectional survey of US physicians was conducted between November 20, 2020, and March 23, 2021. Data analysis was performed from March to July 2023.Main Outcomes and MeasuresBurnout was measured using the Maslach Burnout Index, and professional fulfillment was measured using the Stanford Professional Fulfillment Index. Number of vacation days taken in the last year, time spent working on patient care and other professional tasks per typical vacation day (ie, work on vacation), electronic health record (EHR) inbox coverage while on vacation, barriers to taking vacation, and standard demographics were collected.ResultsAmong 3024 respondents, 1790 of 3004 (59.6%), took 15 or fewer days of vacation in the last year, with 597 of 3004 (19.9%) taking 5 or fewer days. The majority, 2104 respondents (70.4%), performed patient care–related tasks on vacation, with 988 of 2988 (33.1%) working 30 minutes or more on a typical vacation day. Less than one-half of physicians (1468 of 2991 physicians [49.1%]) reported having full EHR inbox coverage while on vacation. On multivariable analysis adjusting for personal and professional factors, concern about finding someone to cover clinical responsibilities (odds ratio [OR], 0.48 [95% CI, 0.35-0.65] for quite a bit; OR, 0.30 [95% CI, 0.21-0.43] for very much) and financial concerns (OR, 0.49 [95% CI, 0.36-0.66] for quite a bit; OR, 0.38 [95% CI, 0.27-0.54] for very much) were associated with decreased likelihood of taking more than 3 weeks of vacation per year. Taking more than 3 weeks of vacation per year (OR, 0.66 [95% CI, 0.45-0.98] for 16-20 days; OR, 0.59 [95% CI, 0.40-0.86] for &amp;gt;20 days vs none) and having full EHR inbox coverage while on vacation (OR, 0.74; 95% CI, 0.63-0.88) were associated with lower rates of burnout on multivariable analysis, whereas spending 30 minutes or longer per vacation day on patient-related work (OR, 1.58; 95% CI, 1.22-2.04 for 30-60 minutes; OR, 1.97; 95% CI, 1.41-2.77 for 60-90 minutes; OR, 1.92; 95% CI, 1.36-2.73 for &amp;gt;90 minutes) was associated with higher rates of burnout.Conclusions and RelevanceIn this cross-sectional study of 3024 physicians, the number of vacation days taken and performing patient-related work while on vacation were associated with physician burnout. System-level efforts to ensure physicians take adequate vacation and have coverage for clinical responsibilities, including EHR inbox, may reduce physician burnout.
Long-term Outcomes After Surgical Reconstruction of Multiligamentous Knee Injuries: Results at Minimum 10-Year Follow-up
Boos, Alexander M. , Wang, Allen S. , Levy, Bruce A. , Wang, Allen , Boos, Alexander , Hevesi, Mario , Krych, Aaron J. , Stuart, Michael J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 12, 2024 | Volume: 12 | Issue: 1 | Pages: No page available

10.1177/23259671231223188 | PMID 38222026 Get It

Background: Multiligamentous knee injuries (MLKIs) are devastating injuries with concomitant injuries that complicate treatment and recovery. Short-term studies have shown satisfactory patient outcomes after surgical treatment; however, evaluations of long-term outcomes remain scarce. Purpose: To evaluate long-term outcomes after surgically reconstructed MLKIs and further investigate the relationship between patient age on clinical outcomes. Study Design: Case series; Level of evidence, 4. Methods: A total of 55 knees (age, 36 ± 11 years; 24% female subjects) who underwent surgical reconstruction for MLKI between 1992 and 2013 met the study inclusion criteria and were evaluated with postoperative patient-reported outcomes (PROs) including International Knee Documentation Committee (IKDC) score, Lysholm score, visual analog scale (VAS) for pain, Forgotten Joint Score, subjective improvement ratings and surgery satisfaction, and Tegner activity scores. PRO scores, revision, and conversion to arthroplasty were analyzed using descriptive statistics, linear regression, Wilcoxon rank-sum, and Fisher exact tests. Results: At final follow-up (mean, 15 ± 5 years; range, 10-31 years), 67% of the cohort reported subjective improvement in their knee, and 82% reported satisfaction with their surgery. Compared with preoperative scores, there were significant improvements in postoperative VAS pain at rest in the full cohort, age ≤30-year cohort, and age >30-year cohort (4 ± 1 vs 2 ± 2; 4 ± 1 vs 2 ± 3; 4 ± 1 vs 1 ± 2, respectively; P≤ .029 for all) but significant reductions in Tegner scores (6 ± 3 vs 4 ± 2; 7 ± 2 vs 5 ± 2; 5 ± 2 vs 3 ± 1; P≤ .003 for all). Younger patients had higher postoperative Tegner scores than older patients (5 ± 2 vs 3 ± 1, respectively; P = .003), but no other differences in PROs were observed based on age. At a mean 15-year follow-up, 3.6% of the cohort underwent revision ligament surgery and 10.9% required arthroplasty. Conclusion: The majority of the cohort reported modest subjective improvement and were satisfied with their surgery. Gradual but expected age-related decreases in Tegner scores were observed, and some patients demonstrated continued symptomatic and functional limitations, but mean PRO scores remained satisfactory. Revision surgery and conversion to arthroplasty were not commonly required.
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value
Battaglin, Francesca , Millstein, Joshua , Yang, Yan , Xiu, Joanne , Arai, Hiroyuki , Wang, Jingyuan , Innocenti, Federico , Kawanishi, Natsuko , Lenz, Annika , Algaze, Sandra , Zhang, Wu, Khoukaz, Taline, Torres, Evanthia T. Roussos , Seeber, Andreas , Abraham, Jim , Shields, Anthony F. , Goldberg, Richard M. , Lenz, Heinz‐Josef , Arai, Hiroyuki , Lou, Emil , Lenz, Heinz-Josef , Baca, Yasmine , Wang, Jingyuan , Ou, Fang‐Shu , Mumenthaler, Shannon M. , Jayachandran, Priya , Soni, Shivani , Lou, Emil , Philip, Philip A. , Weinberg, Benjamin A. , Marshall, John L , Venook, Alan P. , Korn, Wolfgang Michael

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 11, 2024 | Volume: 12 | Issue: 1 | Pages: e007939

10.1136/jitc-2023-007939 | PMID 38212126 Get It

Background The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated with CCR5 / CCL5 expression in CRC and to determine whether CCR5 / CCL5 levels could impact treatment outcomes. Methods 7604 CRCs tested with NextGen Sequencing on DNA and RNA were analyzed. Molecular features were evaluated according to CCR5 and CCL5 tumor gene expression quartiles. The impact on treatment outcomes was assessed in two cohorts, including 6341 real-world patients and 429 patients from the Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial. Results CCR5 / CCL5 expression was higher in right-sided versus left-sided tumors, and positively associated with consensus molecular subtypes 1 and 4. Higher CCR5 / CCL5 expression was associated with higher tumor mutational burden, deficiency in mismatch repair and programmed cell death ligand 1 (PD-L1) levels. Additionally, high CCR5 / CCL5 were associated with higher immune cell infiltration in the tumor microenvironment (TME) of MMR proficient tumors. Ingenuity pathway analysis revealed upregulation of the programmed cell death protein 1 (PD-1)/PD-L1 cancer immunotherapy pathway, phosphatase and tensin homolog (PTEN) and peroxisome proliferator-activated receptors (PPAR) signaling, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) signaling in cytotoxic T lymphocytes, whereas several inflammation-related pathways were downregulated. Low CCR5 / CCL5 expression was associated with increased benefit from cetuximab-FOLFOX treatment in the CALGB/SWOG 80405 trial, where significant treatment interaction was observed with biologic agents and chemotherapy backbone. Conclusions Our data show a strong association between CCR5/CCL5 gene expression and distinct molecular features, gene expression profiles, TME cell infiltration, and treatment benefit in CRC. Targeting the CCR5/CCL5 axis may have clinical applications in selected CRC subgroups and may play a key role in developing and deploying strategies to modulate the immune TME for CRC treatment.